F. Pouliot, “Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer: Real-world data from 50 consecutive cases treated in a single Canadian center”, CUAJ, vol. 20, no. 6, Feb. 2026.